
Shineco, Inc. TYHT
Shineco, Inc. EV - Enterprise Value | TYHT
Annual EV - Enterprise Value Shineco, Inc.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 22.9 B | 18.9 B | - | 21.3 B | 24.9 B | 17.7 B | 21.7 B | - | 17.8 B | 17.1 B | 19.4 B |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 24.9 B | 17.1 B | 20.2 B |
EV - Enterprise Value of other stocks in the Biotechnology industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Omeros Corporation
OMER
|
661 M | $ 13.23 | -5.71 % | $ 840 M | ||
|
BioLineRx Ltd.
BLRX
|
5.66 B | $ 0.94 | -10.44 % | $ 2.32 B | ||
|
PhaseBio Pharmaceuticals
PHAS
|
226 M | - | 7.4 % | $ 6.29 M | ||
|
Forma Therapeutics Holdings
FMTX
|
452 M | - | - | $ 958 M | ||
|
Blueprint Medicines Corporation
BPMC
|
6.74 B | - | - | $ 8.14 B | ||
|
Horizon Therapeutics Public Limited Company
HZNP
|
22.9 B | - | - | $ 26.6 B | ||
|
Provention Bio
PRVB
|
1.86 B | - | - | $ 2.37 B | ||
|
Reata Pharmaceuticals
RETA
|
1.6 B | - | - | $ 6.29 B | ||
|
PainReform Ltd.
PRFX
|
1.3 M | $ 0.47 | -24.53 % | $ 305 K | ||
|
iTeos Therapeutics
ITOS
|
248 M | - | - | $ 411 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-721 K | $ 1.44 | -2.03 % | $ 2.37 M | ||
|
PolarityTE
PTE
|
-900 K | - | -0.82 % | $ 1.78 M | ||
|
Kronos Bio
KRON
|
-47.8 M | - | 1.49 % | $ 50.8 M | ||
|
Cullinan Management
CGEM
|
850 M | $ 8.9 | -1.93 % | $ 536 M | ||
|
CRISPR Therapeutics AG
CRSP
|
4.38 B | $ 39.15 | 0.57 % | $ 3.52 B | ||
|
Advaxis
ADXS
|
-3.02 M | - | -9.65 % | $ 45.9 M | ||
|
Stoke Therapeutics
STOK
|
1.99 B | $ 26.77 | -0.59 % | $ 1.59 B | ||
|
Trevena
TRVN
|
20.4 M | - | -46.58 % | $ 31.8 M | ||
|
Calithera Biosciences
CALA
|
-17.2 M | - | -10.95 % | $ 876 K | ||
|
Molecular Templates
MTEM
|
29.7 M | - | -23.43 % | $ 495 K | ||
|
Oncorus
ONCR
|
59.4 M | - | -8.54 % | $ 3.19 M | ||
|
BioXcel Therapeutics
BTAI
|
127 M | $ 0.07 | 9.81 % | $ 855 K | ||
|
Novan
NOVN
|
99.6 M | - | -24.84 % | $ 2.64 M | ||
|
CohBar
CWBR
|
410 K | - | -15.44 % | $ 2.2 M | ||
|
NeuBase Therapeutics
NBSE
|
-3.75 M | - | -1.56 % | $ 12.3 M | ||
|
Epizyme
EPZM
|
27.9 M | - | - | $ 249 M | ||
|
Arena Pharmaceuticals
ARNA
|
5.42 B | - | -6.81 % | $ 3.04 B | ||
|
Scopus BioPharma
SCPS
|
3.67 M | - | -48.37 % | $ 3.71 M | ||
|
Nabriva Therapeutics plc
NBRV
|
20.2 M | - | - | $ 4.55 M | ||
|
Annovis Bio
ANVS
|
36.5 M | $ 0.71 | -3.81 % | $ 14.6 M | ||
|
scPharmaceuticals
SCPH
|
18.5 M | - | - | $ 218 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
51.1 M | - | - | $ 105 M | ||
|
Athersys
ATHX
|
-9.04 M | - | 3.77 % | $ 22.4 M | ||
|
Global Blood Therapeutics
GBT
|
1.87 B | - | - | $ 4.62 B | ||
|
Inozyme Pharma
INZY
|
44.3 M | - | - | $ 207 M | ||
|
NanoString Technologies
NSTG
|
655 M | - | -37.43 % | $ 5.1 M | ||
|
Humanigen
HGEN
|
60.3 M | - | -81.12 % | $ 4.28 M | ||
|
CNS Pharmaceuticals
CNSP
|
-2.04 M | $ 3.56 | -9.07 % | $ 1.58 M | ||
|
Sorrento Therapeutics
SRNE
|
471 M | - | -29.58 % | $ 126 M | ||
|
Surface Oncology
SURF
|
-40 B | - | - | $ 59.7 M | ||
|
Sierra Oncology
SRRA
|
197 M | - | -0.05 % | $ 1.34 B | ||
|
Vaccinex
VCNX
|
6.94 M | - | -61.37 % | $ 654 K | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
26.1 M | - | -19.68 % | $ 18.4 M | ||
|
Jounce Therapeutics
JNCE
|
-73.6 M | - | - | $ 98.4 M | ||
|
Cocrystal Pharma
COCP
|
7.76 M | $ 0.93 | -4.11 % | $ 10.5 M | ||
|
Fortress Biotech
FBIO
|
122 M | $ 1.89 | 6.78 % | $ 52.7 M | ||
|
Acorda Therapeutics
ACOR
|
-13.2 M | - | -24.86 % | $ 820 K | ||
|
Longeveron
LGVN
|
16.9 B | $ 1.65 | -9.34 % | $ 29 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-1.05 M | - | -11.43 % | $ 502 K | ||
|
Immunic
IMUX
|
160 M | $ 7.0 | -5.28 % | $ 1.09 B |